Microbiome diagnostic market is anticipated to grow at a CAGR of 11.4% during the forecast period (2024-2031). The growing adoption of advanced technologies such as 16S rRNA sequencing, shotgun metagenomics, and metatranscriptomics with increasing demand for the human microbiome are key factors supporting the growth of the market globally. The market players are introducing microbiome diagnostic solutions that further bolster the market growth. Through these collaborations, industry companies and academic researchers work together to develop new diagnostic products based on the microbiome and to advance understanding of the microbiome's role in health and disease.

Market Dynamics

Increasing Integration of machine learning and bioinformatics

Growing developments in computational technology, such as bioinformatics and machine learning, have made it easy to detect microbiome-specific diagnoses, resulting in accurate diagnoses for certain diseases. Computational tools are increasingly utilized in a large number of microbiome data for the identification of patterns and potential biomarkers associated with health conditions. Further rapid development of machine learning techniques has opened up the data-dense field of microbiome research for novel therapeutic, diagnostic, and prognostic applications targeting a wide range of disorders, which could substantially improve healthcare practices in the era of precision medicine.

Increasing adoption of multi-omics data for microbiome functional activities

Increasing adoption of multi-omics data for microbiome fictional activities with integrating the data from multi-omic approaches provides additional insight into microbiome functions. For instance, integrating metagenomics and metatranscriptomics provides a calculation of transcript/gene ratios, which is indicative of gene transcriptional activation or repression. Additionally, multi-omic studies of the microbiome can provide insight into the mechanisms underlying host-microbe interactions. As more omics layers are considered, increasingly sophisticated statistical methods are required to integrate them.

Market Segmentation

Our in-depth analysis of the global microbiome diagnostic market includes the following segments by product, technology and end-users:

• Based on product, the market is sub-segmented into reagents & kits and instruments.

• Based on technology, the market is sub-segmented into 16S rRNA sequencing, shotgun metagenomics, metatranscriptomics, and other (biomarkers).

• Based on end-users, the market is sub-segmented into hospitals, academic and research institutes, and biotechnology and pharmaceutical companies.

Reagents & Kits is Projected to Emerge as the Largest Segment

Based on the product, the global microbiome diagnostic market is sub-segmented into reagents & kits and instruments. Among these, the reagents & kits sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes the growing adoption of reagents and kits for microbiome diagnosing and monitoring disease, for providing prognoses, and for predicting treatment responses. For instance, MACHEREY-NAGEL GmbH & Co. KG offers reagents & kits designed to purify DNA from a variety of sample inputs, including stool, soil, and biofilms for microbiome and metagenome analysis.

Academic and Research Institutes Sub-segment to Hold a Considerable Market Share

Among the end-users, the academic and research institutes sub-segment holds a considerable market share owing to the increasing number of microbial research institutes for microbiome diagnostic studies. For instance, in March 2023, Cedars-Sinai launched a microbiome research institute that supports investigators studying of microbiome includes a diverse collection of bacteria, fungi, and viruses that live in and on the human body, and play a role in health. The major advancements in microbiome research, including technical, practical, and conceptual advancements, result in enhanced disease diagnosis, medicine development, and personalized interventions.

Regional Outlook

The global microbiome diagnostic market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). 

An increasing number of biotechnology and pharmaceutical companies in Europe

• Increasing incidences of diseases, the collaboration between microbiome research and academic institutes for microbiome research, and growing demand for personalized medicine in the region.

• Market players in the region provide advanced technology-based microbiome diagnosis using multi-omics data for microbiome fictional activities.

Global Microbiome Diagnostic Market Growth by Region 2024-2031

North America Holds Major Market Share

Among all the regions, North America holds a significant share owing to the presence of an enormous number of providers offering microbiome diagnostics. Factors such as the availability of the advanced health sector and the critical emerging product manufacturers are driving the market growth. In addition, the development and commercialization of pathogen-specific reagent/diagnostic kits have resulted in improved sample usage and the adoption of a well-defined clinical technique for specific disease diagnoses. The market players in the region are developing advanced microbiome diagnostics. For instance, in January 2023, Micronoma Inc. developed early cancer detection with a microbiome-driven liquid biopsy platform. The OncobiotaLUNG assay is the blood microbiome-driven liquid biopsy created to detect lung carcinomas in their earliest stages.

Market Players Outlook

*Note: Major Players Sorted in No Particular Order.

The major companies serving the global microbiome diagnostic market include Bio-Rad Laboratories, Inc., Illumina, Inc., Merck KGaA, Takara Bio Inc., and Thermo Fisher Scientific Inc., among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. For instance,

• In June 2023, Biome Diagnostics GmbH and SanusX partnered for diagnostics and applications related to the intestinal microbiome for growth in innovative diagnostic procedures with SanusX.BiomeDx utilizes machine learning and artificial intelligence to interpret the intestinal microbiome for medical purposes.

• In February 2023, Microba launched next-generation healthcare testing MetaXplore™. The MetaXplore™ range provides diagnostic gastrointestinal health testing together with metagenomic gut microbiome analysis. The MetaXplore™ test range is expected to expand the total addressable market for Microba’s testing products.

• In June 2021, Illumina and Microba Life Sciences partnered to accelerate microbiome research. The partnership brings together Illumina’s NGS tools and Microba’s high-quality proprietary gut microbiome analysis platform to generate the accurate metagenomic data that researchers require to fuel discoveries.

The Report Covers

• Market value data analysis of 2023 and forecast to 2031.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global microbiome diagnostic market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.